<unk>  is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A). VEGF-A is a growth factor protein that stimulates angiogenesis in a variety of diseases, especially in cancer.<unk>  was the first available angiogenesis inhibitor in the United States.
Bevacizumab
Necitumumab
Bortezomib
Panitumumab
Sunitinib
Ranibizumab
Ruxolitinib
Ceritinib